down arrow

Allurion Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02008G1022
USD
1.73
0.05 (2.98%)

Dec 09

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.631.73

52 Week

1.0216.81
Valuation
Technical
Day's Volume

CASH

19.23 k

Shareholding (Mar 2025)

FII

2.31%

Held by 15 FIIs

DII

94.84%

Held by 2 DIIs

Promoter

0.85%

How big is Allurion Technologies, Inc.?

22-Jun-2025

As of Jun 18, Allurion Technologies, Inc. has a market capitalization of 19.02 million and reported net sales of 28.31 million, with a net profit of -24.35 million. The balance sheet shows shareholder's funds at -77.98 million and total assets of 32.81 million.

As of Jun 18, Allurion Technologies, Inc. has a market capitalization of 19.02 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 28.31 million for the latest four quarters. However, it also recorded a net profit of -24.35 million during the same period, indicating a loss.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds at -77.98 million and total assets amounting to 32.81 million.

Read More

What does Allurion Technologies, Inc. do?

22-Jun-2025

Allurion Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $6 million and a net profit of $7 million as of March 2025. Key metrics include a market cap of $19.02 million, a return on equity of 54.67%, and no dividend yield.

Overview: <BR>Allurion Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 19.02 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.16 <BR>Return on Equity: 54.67% <BR>Price to Book: -0.27<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Allurion Technologies, Inc. overvalued or undervalued?

25-Jun-2025

As of August 9, 2023, Allurion Technologies, Inc. is considered risky and overvalued, with a negative Price to Book Value of -0.29, a P/E ratio of -0.4984, and a year-to-date stock performance decline of 77.58%, significantly underperforming the S&P 500's 2.44% return.

As of 9 August 2023, the valuation grade for Allurion Technologies, Inc. has moved from does not qualify to risky. Based on the analysis, the company appears to be overvalued. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at -0.29, indicating negative equity. Additionally, the EV to Sales ratio is 1.11, suggesting that investors are paying more than the company's sales would justify.<BR><BR>In comparison to its peers, Allurion Technologies has a P/E ratio of -0.4984, which is significantly higher than Pulse Biosciences, Inc. at -17.3411 and NeuroPace, Inc. at -14.1563, both of which also fall under the risky category. The company's recent stock performance has been poor, with a year-to-date return of -77.58%, contrasting sharply with the S&P 500's return of 2.44% over the same period, reinforcing the notion that Allurion Technologies is currently overvalued.

Read More

Is Allurion Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Allurion Technologies, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -80.93%.

As of 25 August 2025, the technical trend for Allurion Technologies, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bullish on a monthly basis but shows no signal weekly. However, Bollinger Bands and KST indicate bearish trends on both weekly and monthly levels. Moving averages are bearish on a daily basis, and Dow Theory suggests a mildly bullish stance weekly with no trend monthly. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -80.93% versus the S&P 500's 12.22%, and a one-year return of -87.2% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.96
  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2

Negative results in Jun 25

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.26

stock-summary
Return on Equity

68.55%

stock-summary
Price to Book

-0.26

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.91%
0%
-19.91%
6 Months
-36.16%
0%
-36.16%
1 Year
-81.64%
0%
-81.64%
2 Years
-97.92%
0%
-97.92%
3 Years
-82.79%
0%
-82.79%
4 Years
-82.29%
0%
-82.29%
5 Years
0%
0%
0.0%

Allurion Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Allurion Technologies Hits 52-Week Low at $1.29 Amidst Financial Struggles

Allurion Technologies Hits 52-Week Low at $1.29 Amidst Financial Struggles

Allurion Technologies, Inc. has reached a new 52-week low, experiencing a significant decline in stock price over the past year. The company, with a market capitalization of approximately USD 17 million, faces challenges including a negative book value and high debt-to-equity ratio, despite a reported increase in profits.

Read More
Allurion Technologies Hits 52-Week Low at $1.30 Amid Financial Struggles

Allurion Technologies Hits 52-Week Low at $1.30 Amid Financial Struggles

Allurion Technologies, Inc. has reached a new 52-week low, experiencing a significant decline in stock price over the past year. The company, with a market capitalization of approximately USD 17 million, faces financial challenges, including negative book value and losses, raising concerns about its long-term viability.

Read More
Allurion Technologies Hits 52-Week Low at $1.35 Amid Financial Struggles

Allurion Technologies Hits 52-Week Low at $1.35 Amid Financial Struggles

Allurion Technologies, Inc. has reached a new 52-week low, reflecting a substantial decline in its stock price over the past year. The company, with a market capitalization of approximately USD 17 million, reported net sales of USD 3.38 million and faces challenges including rising raw material costs and a negative book value.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
175.54%
EBIT Growth (5y)
-354.50%
EBIT to Interest (avg)
-13.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.14
Tax Ratio
3.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
34.21%
ROCE (avg)
0
ROE (avg)
0.72%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.29
EV to EBIT
-0.82
EV to EBITDA
-0.84
EV to Capital Employed
-0.54
EV to Sales
1.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (2.01%)

Foreign Institutions

Held by 15 Foreign Institutions (2.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -39.29% vs 0.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -520.00% vs 84.38% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.40",
          "val2": "5.60",
          "chgp": "-39.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.80",
          "val2": "-3.20",
          "chgp": "-237.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "2.20",
          "chgp": "-45.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.30",
          "val2": "-1.50",
          "chgp": "-520.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,300.40%",
          "val2": "-606.10%",
          "chgp": "-269.43%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.00% vs -16.67% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.29% vs -102.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.10",
          "val2": "53.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.30",
          "val2": "-77.30",
          "chgp": "41.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "10.60",
          "chgp": "-78.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "22.60",
          "val2": "8.90",
          "chgp": "153.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.10",
          "val2": "-82.30",
          "chgp": "68.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,441.90%",
          "val2": "-1,460.30%",
          "chgp": "1.84%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
3.40
5.60
-39.29%
Operating Profit (PBDIT) excl Other Income
-10.80
-3.20
-237.50%
Interest
0.00
0.00
Exceptional Items
1.20
2.20
-45.45%
Consolidate Net Profit
-9.30
-1.50
-520.00%
Operating Profit Margin (Excl OI)
-3,300.40%
-606.10%
-269.43%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -39.29% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -520.00% vs 84.38% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
32.10
53.50
-40.00%
Operating Profit (PBDIT) excl Other Income
-45.30
-77.30
41.40%
Interest
2.30
10.60
-78.30%
Exceptional Items
22.60
8.90
153.93%
Consolidate Net Profit
-26.10
-82.30
68.29%
Operating Profit Margin (Excl OI)
-1,441.90%
-1,460.30%
1.84%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -40.00% vs -16.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.29% vs -102.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Allurion Technologies, Inc. stock-summary
stock-summary
Allurion Technologies, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."